Diabetes and myocardial infarction

Bailliere's Best Practice and Research in Clinical Endocrinology and Metabolism

Volumn 13, Issue 2, 1999, Pages 331-343

  Fisher, Miles ^a  

^a ROYAL ALEXANDRA HOSPITAL   (United Kingdom)

Author keywords

Diabetes mellitus; DIGAMI; Intravenous insulin; Myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; INSULIN; LISINOPRIL; PRAVASTATIN; SIMVASTATIN; STATIN;

BLOOD CLOT LYSIS; CAUSE OF DEATH; CLINICAL TRIAL; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; METABOLIC REGULATION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; SECONDARY PREVENTION;

EID: 0033495318     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1053/beem.1999.0024     Document Type: Article

References (56)

1. Fisher B M. Diabetes mellitus and myocardial infarction: a time to act or a time to wait? Diabetic Medicine. 15:1998;275.
2. Haffner S M, Lehto S, Ronnemaa T. Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New England Journal of Medicine. 339:1998;229-234.
3. Herlitz J, Malmberg K, Karlson B W. Mortality and morbidity during a five-year follow-up of diabetics with myocardial infarction. Acta Medica Scandinavica. 224:1988;31-38.
4. Zuanetti G, Latini R, Maggioni A P. Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study. Journal of the American College of Cardiology. 22:1993;1788-1794.
5. Herlitz J, Bang A, Karlson B W. Mortality, place and mode of death and reinfarction during a period of five years after acute myocardial infarction in diabetic and non diabetic patients. Cardiology. 87:1996;423-428.
6. Herlitz J, Malmberg K. How to improve the cardiac prognosis for diabetes. Diabetes Care. 22:1999;B89-B96.
7. Yudkin J S, Oswald G A. Hyperglycaemia, diabetes and myocardial infarction. Diabetic Medicine. 4:1987;13-18.
8. Willerson J T, Hutcheson D R, Leshin S J. Serum glucagon and insulin levels and their relationship to blood glucose values in patients with acute myocardial infarction and acute coronary insufficiency. American Journal of Medicine. 57:1974;747-753.
9. Husband D J, Alberti K GMM, Julian D G. Methods for the control of diabetes after acute myocardial infarction. Diabetes Care. 8:1985;261-267.
10. Gwilt D J, Nattrass M, Pentecost B L. Use of low-dose insulin infusions in diabetics after myocardial infarction. British Medical Journal. 285:1982;1402-1404.
11. Gwilt D J, Petri M, Lamb P. Effect of intravenous insulin infusion on mortality among diabetic patients after myocardial infarction. British Heart Journal. 51:1984;626-630.
12. Clark R S, English M, McNeill G P, Newton R W. Effect of intravenous infusion of insulin in diabetics with acute myocardial infarction. British Medical Journal. 291:1985;303-305.
13. Davies R R, Newton R W, McNeill G P. Metabolic control in diabetic subjects following myocardial infarction: difficulties in improving blood glucose levels by intravenous insulin infusion. Scottish Medical Journal. 36:1991;74-76.
14. Malmberg K A, Efendic S, Ryden L E. Feasibility of insulin-glucose infusion in diabetic patients with acute myocardial infarction. A report from the multicenter trial. Diabetes Care. 17:1994;1007-1014.
15. Malmberg K, Ryden L, Efendic S. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI Study): effects on mortality at 1 year. Journal of the American College of Cardiology. 26:1995;57-65.
16. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. British Medical Journal. 314:1997;1512-1515.
17. Fisher B M. Insulin infusion in diabetic patients with acute myocardial infarction. Effective components of care and patients who might benefit must be determined. British Medical Journal. 314:1997;145.
18. Muhlhauser I, Sawicki P T, Berger M. Possible risk of sulphonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease. Diabetologia. 40:1997;1492-1493.
19. Diabetes. 19:1970;789-830.
20. Lancet. 352:1998;837-853.
21. Malmberg K, Ryden L, Hamsten A. Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. European Heart Journal. 17:1996;1337-1344.
22. Malmberg K, Ryden L, Hamsten A. Mortality prediction in diabetic patients with myocardial infarction: experiences from the DIGAMI study. Cardiovascular Research. 34:1997;248-253.
23. Fisher B M. Diabetes and myocardial infarction: critical evaluation of the DIGAMI study. Practical Diabetes International. 15:1998;101-102.
24. Frier B M. Diabetes and myocardial infarction. Diabetes Reviews International. 7:1998;1-2.
25. Davey G, Mckeigue P. Insulin infusion in diabetic patients with acute myocardial infarction. Effective in diabetes, but patients with glucose intolerance may also benefit. British Medical Journal. 313:1996;639-640.
26. Yudkin J S. Insulin infusion in diabetic patients with acute myocardial infarction. Insulin should be continued for 12 months after acute event. British Medical Journal. 314:1997;145-146.
27. Nattrass M. Managing diabetes after myocardial infarction. Time for a more aggressive approach. British Medical Journal. 314:1997;1497.
28. McLaughlin K. Intensive insulin treatment after acute myocardial infarction in diabetes mellitus. Intensive insulin regimens in primary prevention should be assessed. British Medical Journal. 315:1997;544-545.
29. Yudkin J S. Managing the diabetic patient with acute myocardial infarction. Diabetic Medicine. 15:1998;276-281.
30. Lawrence I G, Davies M J. Diabetes and myocardial infarction: do we have time to wait? Practical Diabetes International. 16:1999;43-46.
31. Shaw K M. The DIGAMI debate continues. Practical Diabetes International. 16:1999;31-32.
32. Zuanetti G, Latini R. Impact of pharmacological treatment on mortality after myocardial infarction in diabetic patients. Journal of Diabetes and its Complications. 11:1997;131-136.
33. MacDonald T M, Butler R, Newton R W, Morris A D. Which drugs benefit diabetic patients for secondary prevention of myocardial infarction? Diabetic Medicine. 15:1998;282-289.
34. Fisher B M. Diabetes and myocardial infarction. International Diabetes Reviews. 1999;15-19.
35. Lynch M, Gammage M D, Lamb P. Acute myocardial infarction in diabetic patients in the thrombolytic era. Diabetic Medicine. 11:1994;162-165.
36. Lancet. 343:1994;311-322.
37. Jelesoff N E, Feingloss M, Granger C B, Califf R M. Outcomes of diabetic patients following acute myocardial infarction: a review of the major thrombolytic trials. Coronary Artery Disease. 7:1996;732-743.
38. Lancet. ii:1988;349-360.
39. British Medical Journal. 398:1994;81-106.
40. Yudkin J S. Which diabetic patients should be taking aspirin? British Medical Journal. 311:1995;641-642.
41. Hansson L, Zanchetti A, Carruthers S G. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 351:1998;1755-1762.
42. Kendall M J, Lynch K P, Hjalmarson A, Kjekshus J. B-blockers and sudden cardiac death. Annals of Internal Medicine. 123:1995;538-567.
43. Zuanetti G, Latini R, Maggioni A P. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction. Circulation. 94:1997;4239-4245.
44. Lancet. 344:1994;1383-1389.
45. Pyorala K, Pedersen T R, Kjekshus J. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 20:1997;614-620.
46. Sacks F M, Pfeffer M A, Moye L A. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New England Journal of Medicine. 335:1996;1001-1009.
47. New England Journal of Medicine. 339:1998;1349-1357.
48. Goldberg R B, Mellies M J, Sacks F M. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the Cholesterol And Recurrent Events (CARE) Trial. Circulation. 98:1998;2513-2519.
49. American Journal of Cardiology. 75:1995;894-903.
50. Lawson M L, Gerstein H C, Tsui E, Zinman B. Effect of intensive therapy on early macrovascular disease in young individuals with Type 1 diabetes. A systematic review and meta-analysis. Diabetic Care. 22:1999;B35-B39.
51. Lancet. 352:1998;854-865.
52. British Medical Journal. 317:1998;703-713.
53. Curb J D, Pressel S L, Cutler J A. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Journal of the American Medical Association. 276:1996;1886-1892.
54. Tuomilehto J, Rastenyte D, Birkenhager W H. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. New England Journal of Medicine. 340:1999;677-684.
55. Estacio R O, Jeffers R W, Hiatt W R. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. New England Journal of Medicine. 338:1998;645-652.
56. Tatti P, Pahor M, Byington R P. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 21:1998;597-603.